The need for worldwide policy and action plans for rare diseases

John Forman, Domenica Taruscio(Istituto Superiore di Sanità), Virginia A. Llera, Luis A. Barrera(Pontificia Universidad Javeriana), Timothy R. Coté(National Organization for Rare Disorders), Catarina Edfjäll, Desirée Gavhed(Karolinska University Hospital), Marlene E. Haffner, Yukiko Nishimura(The University of Tokyo), Manuel Posada de la Paz(Instituto de Salud Carlos III), Erik Tambuyzer, Stephen C. Groft(National Institutes of Health), Jan‐Inge Henter(Karolinska University Hospital), on behalf of the International Conference for Rare Diseases and Orphan Drugs (ICORD)
Acta Paediatrica
April 20, 2012
Cited by 102Open Access
Full Text

Abstract

UNLABELLED: There are more than 6000 rare diseases (defined as affecting <5/10 000 individuals in Europe, <200 000 people in the United States). The rarity can create problems including: difficulties in obtaining timely, accurate diagnoses; lack of experienced healthcare providers; useful, reliable and timely information may be hard to find; research activities are less common; developing new medicines may not be economically feasible; treatments are sometimes very expensive; and in developing countries, the problems are compounded by other resource limitations. Emphasis is required to support appropriate research and development leading to better prevention, diagnosis and treatments of rare diseases. Notably, clinical trials using already existing drugs may result in new, affordable, treatment strategies. Moreover, rare diseases may teach us about common disorders. CONCLUSIONS: Countries are encouraged to implement specific research and development activities within their individual capabilities, so that patients worldwide have equal access to necessary interventions to maximize the potential of every individual.


Related Papers

No related papers found

Powered by citation graph analysis